Orexigen Therapeutics, Inc. Reports Inducement Grant Under The Nasdaq Stock Market -- New York Listing Rule 5635(c)(4)

SAN DIEGO, March 1 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity, today announced that on February 26, 2010 the Compensation Committee of the Company’s Board of Directors approved the grant of inducement stock options to purchase a total of 24,000 shares of common stock to two new employees.

Both stock options were granted as an inducement material to the new employees’ entering into employment with Orexigen Therapeutics in accordance with NASDAQ listing Rule 5635(c)(4).

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,” “potential,” “suggests,” “assuming,” “designed” and similar expressions are intended to identify forward-looking statements. These statements are based on the Company’s current beliefs and expectations. These forward-looking statements include statements regarding the potential for, and timing of, filing an NDA for Contrave. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: risks inherent in the continued analyses of clinical trial results, including Contrave Phase 3 trials; the uncertainty of the FDA approval process and other regulatory requirements; the therapeutic and commercial value of Contrave and Empatic; reliance on third parties to assist with the development of Contrave and Empatic and the regulatory submissions related thereto; the potential for adverse safety findings relating to Contrave or Empatic; and other risks described in the Company’s filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

CONTACT: Graham Cooper of Orexigen Therapeutics, +1-858-875-8600; or Liz
Frank of WCG, +1-212-301-7216, for Orexigen Therapeutics

Web site: http://www.Orexigen.com/

MORE ON THIS TOPIC